Newsletter Tool

Today's Rundown

AstraZeneca, Sanofi reveal mixed hand in high-stakes RSV game, with hospitalization miss tarnishing primary endpoint hit
As Russia stacked troops on Ukraine's border, Karuna's trial partners got ready
Roche plans 4-year late-stage trial for Alzheimer's candidate while awaiting crucial H2 readout
Sponsored: The Importance of the Patient in Advancing Care in Rare Diseases
Atlas lands $450M fund to build fresh batch of biotechs
Avalo adjusts almost entire pipeline weeks after CEO, CFO say sayonara
Roche, Sanofi, Novo Nordisk and more pledge support to Ukraine as industry condemns Russian invasion
COVID-19, even mild, associated with heart complications up to a year post-infection, study finds
AstraZeneca's Alexion wants to make sure rare is still seen and heard
1nHealth, ObvioHealth team to aid firms struggling with decentralized trials
Novo Nordisk, citing strong Wegovy demand, doubles 2025 sales target for obesity franchise
House Lawmakers eye loan repayments, nursing staff ratios to ease workforce shortages

Featured Story

AstraZeneca, Sanofi reveal mixed hand in high-stakes RSV game, with hospitalization miss tarnishing primary endpoint hit

By Nick Paul Taylor

There’s more trouble in the respiratory syncytial virus (RSV) race. Days after GlaxoSmithKline stopped its maternal vaccine studies, AstraZeneca and Sanofi have revealed their antibody prospect failed to reduce infant hospitalization in a phase 3 clinical trial.

As Russia stacked troops on Ukraine's border, Karuna's trial partners got ready

By Max Bayer

When Russia began to stack troops along Ukraine's border—up to 190,000 of them—Karuna Therapeutics' partners began to prepare clinical trial participants for the company's schizophrenia treatment in psychiatric hospitals across the country.

Roche plans 4-year late-stage trial for Alzheimer's candidate while awaiting crucial H2 readout

By Kyle LaHucik

Roche is gearing up for a four-year phase 3 study of its Alzheimer's drug gantenerumab, and one trial site in Florida confirmed to Fierce Biotech that patient screening has already gotten underway for the trial, slated to begin June 24.

Atlas Venture has gathered another pot of cash for biotech creation. Less than two years after disclosing a $400 million fund, the Massachusetts-based VC shop has reeled in still more money for its next wave of new startups.

Avalo adjusts almost entire pipeline weeks after CEO, CFO say sayonara

By Kyle LaHucik

Avalo Therapeutics, formerly Cerecor, readjusted almost its entire pipeline Wednesday, just weeks after the biotech's CEO and finance chief hit the exit.

Roche, Sanofi, Novo Nordisk and more pledge support to Ukraine as industry condemns Russian invasion

By Fraiser Kansteiner

The contingent of pharma companies condemning Russia’s invasion of Ukraine—and pledging to help keep the beleaguered nation’s healthcare system afloat—is growing.

COVID-19, even mild, associated with heart complications up to a year post-infection, study finds

By Anastassia Gliadkovskaya

Dysrhythmia was the most common individual outcome seen in patients analyzed, and those in ICU were most likely to develop complications across all categories.

AstraZeneca's Alexion wants to make sure rare is still seen and heard

By Sharon Klahr Coey

It’s a rather bitter irony that so many people suffer from a rare disease—about 300 million people worldwide. There are around 7,000 different rare diseases, of which sadly only 5% have a viable treatment option.

1nHealth, ObvioHealth team to aid firms struggling with decentralized trials

By Gareth Macdonald

Industry interest in decentralized and hybrid trials is not matched by experience, according to 1nHealth and ObvioHealth, which say their partnership will aid drug developers as they transition to remote and siteless clinical studies.

Novo Nordisk, citing strong Wegovy demand, doubles 2025 sales target for obesity franchise

By Fraiser Kansteiner

Novo Nordisk is gunning for more than 25 billion Danish krone ($3.72 billion) in obesity sales by 2025, the company said Thursday. Novo had previously aimed to generate around 11.35 billion Danish krone (roughly $1.69 billion) by the middle of the decade, based on earlier weight loss med Saxenda’s 2019 sales of 5.7 billion Danish krone ($849 million).